ESTRO37_ProgrammeBook

SYMPOSIUM Immuno-radiotherapy: the critical influence of radiation dose, scheduling

and dose per fraction 14:30 - 15:45  | ROOM 116

SUNDAY 22 APRIL 2018

There is enormous interest in combining radiotherapy with immune checkpoint inhibitors, and while a number of different agents are currently being tested, important questions regarding radiotherapy dose, schedule and dose per fraction remain unanswered. In this Interdisciplinary Session an international panel of clinicians and scientists will present the latest laboratory and clinical data and consider (i) what additional data is required (ii) which radiotherapy/IO schedules are the most promising and (iii) the key mechanisms involved. Alan Melcher will provide an overview of the molecular interactions between radiotherapy and the immune system. Sandra Demaria will review the roles of radiation-induced cytosolic DNA and the exonuclease TREX1 in activation of dendritic cells. Dirk de Ruysscher will present clinical data informing dose and scheduling strategies and Fiona McDonald will review ongoing and upcoming clinical trials evaluating different RT schedules in combination with immunotherapy. 14:30 > Overview of the molecular interactions between radiotherapy and the immune system and immune checkpoint inhibitors Speaker: A. Melcher (United Kingdom) 14:48 > From local to abscopal: preclinical evidence that radiation dose and fractionation determine its synergy with immunotherapy Speaker: S. Demaria (USA) 15:06 > Clinical data informing dose/dose per fraction and scheduling strategies Speaker: D. De Ruysscher (The Netherlands) 15:24 > Ongoing and upcoming clinical trials evaluating different RT schedules in combination with immunotherapy Speaker: F. McDonald (United Kingdom) SYMPOSIUM New strategies to target hypoxia in combination with radiotherapy 14:30 - 15:45  | ROOM 120-121 Exciting new hypoxia-targeting strategies aimed to selectively eliminate hypoxic cancer cells, impede recurrence and improve patient survival in the context of radiotherapy have emerged. Approaches and clinical promises to impair hypoxia tolerance, reduce oxygen consumption and block DNA damage signaling under Chair: A. Chalmers (United Kingdom) Co-Chair: I. Verbrugge (The Netherlands)

SP-0333

SP-0334

SP-0335

SP-0336

SCIENTIFIC PROGRAMME | Programme and Exhibition Guide

122